Professor Susan M. Bailey, Ph.D., joined KromaTiD as one of the founders of the company in 2007 and currently serves as the corporate Secretary. Dr. Bailey is currently an Associate Professor in the Department of Environmental and Radiological Health Sciences at Colorado State University. She previously worked at the Los Alamos National Laboratory, Bioscience Division, doing research involving the development and application of the CO-FISH technique. Dr. Bailey’s current research program, funded by the NIH and NASA, revolves around what chromosomes and telomeres can tell us about cancer and other human disease states. She also serves on the Editorial Board of two scientific journals, is an author on over 50 peer-reviewed publications, 3 book chapters and an inventor on one patent application. Dr. Bailey received her B.S. degree in Biology from Colorado State University, and M.S. and Ph.D. degrees in Biomedical Sciences from the University of New Mexico, School of Medicine.
Professor F. Andrew Ray, Ph.D., joined KromaTiD as one of the founders of the company in 2007. Dr. Ray is currently an Associate Professor in the Department of Environmental and Radiological Health Sciences at Colorado State University. Previously, he was a staff scientist at the Los Alamos National Laboratory. As a graduate student he published a landmark paper showing that a viral protein was responsible for generating chromosomal instability in human cells enabling subsequent transformation to a tumorigenic phenotype. He was formerly an Associate Professor in the Department of Microbiology, Immunology and Molecular Genetics at Albany Medical College. He is a contributing author on 40 scientific publications and an inventor on three issued and four pending patents. Dr. Ray received a B.S. in Biology from Stetson University and M.S. and Ph.D. degrees in Medical Sciences from the School of Medicine at the University of New Mexico.
Professor Michael Cornforth, Ph.D., joined KromaTiD as one of the founders of the Company in 2007. Dr. Cornforth is currently a Professor in the Department of Radiation Oncology at The University of Texas Medical Branch at Galveston, Texas (UTMB). His formal training is in radiation biology with emphasis on the study of chromosome aberrations produced by various forms of ionizing radiation, and how chromosomal rearrangements are affected by changes in ionization density, total dose, and the rate at which total dose is delivered. Current funding includes support from the Department of Energy (DOE), NIH (NIAID) and NASA. Dr. Cornforth previously worked at the Los Alamos National Laboratory, has served on the editorial boards of two international journals, as Councilor for Biology for the Radiation Research Society, and currently holds a position on the Scientific Council of the Radiation Effects Research Foundation in Hiroshima, Japan. He has authored numerous peer-reviewed articles in scientific journals, and has published three book chapters dealing with radiation effects on chromosomes. Professor Cornforth received his doctoral degree at Colorado State University.
Professor Edwin H. Goodwin, Ph.D., is currently a member of KromaTiD’s Scientific Advisory Board. As a graduate student, Dr. Goodwin participated in an NIH-funded initiative to evaluate charged-particle radiations as a therapy for cancer. Using the cyclotrons at Lawrence Berkeley Laboratory, Professor Goodwin analyzed chromosome fragmentation patterns in an effort to understand the biological effects of these exotic radiations. His studies of radiation continued at Los Alamos National Laboratory in research funded by the Department of Energy’s radon and low-dose radiation risk assessment programs. While at Los Alamos, Professor Goodwin invented Chromosome Orientation Fluorescence in situ Hybridization (CO-FISH). Application of CO-FISH reveals the orientation of DNA sequences in chromosomes, information that has proven to be useful in studies of repetitive DNA sequences and telomere biology. He received B.S. and M.S. degrees in physics from Fairleigh Dickinson University (Teaneck, NJ) and a Ph.D. in biophysics from the University of California (Berkeley, CA).
Professor Joe W. Gray, Ph.D., is the co-inventor of the FISH (fluorescence in situ hybridization) technique and is currently a member of KromaTiD’s Scientific Advisory Board. Dr. Gray is currently the Associate Director for translational research for the Oregon Health and Science University Knight Cancer Institute, he holds the Gordon Moore Endowed Chair, is chair of the Department of Biomedical Engineering and Director of the Center for Spatial Systems Biomedicine. In addition to his roles at Oregon Health and Science University, he is a visiting senior scientist at Lawrence Berkeley National Laboratory and emeritus professor at the University of California, San Francisco. Dr. Gray’s work is described in over 400 publications and in 73 US patents. He is a Fellow of the American Association for the Advancement of Science and the American Institute for Medical and Biological Engineering, an elected a member of the Institute of Medicine of the National Academy of Sciences and Chair of the National Institutes of Health, Frederick Advisory Committee to the Director of the National Cancer Institute.
Professor Julie Korenberg, M.D., Ph.D., is currently a member of KromaTiD’s Scientific Advisory Board and is a USTAR Professor of Pediatrics and Director of the Center for Integrated Neuroscience and Human Behavior at the University of Utah. Dr. Korenberg’s work has focused on understanding the genetic roots of developmental disorders including Down’s and Williams syndromes. Her team studies brain mechanisms that underlie the formation of strong human relationships (“affiliative behavior”) and is investigating the development of drugs that modulate brain circuits involved in these behaviors. Dr. Korenberg previously was the Vice Chair for Research in the Department of Pediatrics and the Geri & Richard Brawerman Chair of Molecular Genetics at the David Geffen School of Medicine at UCLA. She earned her Ph.D. in Medical Genetics from the University of Wisconsin and her M.D. from the University of Miami School of Medicine.
Professor Joel S. Bedford, Ph.D., Chairman